Filing Flows › Chemed (CHE) › Q3 2026 › vs Q2 2026
Chemed (CHE) Q3 2026 vs Q2 2026 (quarter over quarter)
Chemed's revenue rose $17.7M (+3%) from $673M in Q2 2026 to $691M in Q3 2026. The biggest changes: VITAS +$14.1M (+3%); Roto-Rooter +$3.6M (+2%). Operating margin 14.0% against 13.2% (+0.7 pts).
Chemed, Q3 2026: revenue $691M (+11% year over year), operating margin 14.0%, net earnings $71.6M, operating cash flow $56.6M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 14.0% | 13.2% | +0.7 pts |
| Net margin | 10.4% | 10.1% | +0.3 pts |
| Free cash flow margin | 5.5% | 10.3% | -4.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| VITAS | $457M | $443M | $14.1M | +3% |
| Roto-Rooter | $234M | $230M | $3.6M | +2% |
| Revenue | $691M | $673M | $17.7M | +3% |
| Operating profit | $96.4M | $89.2M | $7.2M | +8% |
| Costs & expenses | $595M | $584M | $10.5M | +2% |
| Pre-tax earnings | $96.7M | $91.3M | $5.4M | +6% |
| Cost of revenue | $458M | $452M | $6.2M | +1% |
| SG&A | $111M | $115M | −$3.7M | -3% |
| Other operating costs | $25.1M | $17.1M | $8.0M | +47% |
| Net earnings | $71.6M | $67.7M | $3.9M | +6% |
| Income tax | $25.1M | $23.6M | $1.4M | +6% |
| Depreciation & amortization | $17.4M | $17.0M | $415K | +2% |
| Working capital & other | $32.5M | −$124K | $32.6M | — |
| Operating cash flow | $56.6M | $84.8M | −$28.2M | -33% |
| Free cash flow (OCF − capex) | $37.9M | $69.3M | −$31.4M | -45% |
| Capital expenditures | $18.7M | $15.5M | $3.2M | +21% |
Questions
How much did Chemed's revenue grow quarter over quarter in Q3 2026?
Chemed's revenue rose $17.7M (+3%) from $673M in Q2 2026 to $691M in Q3 2026.
What drove Chemed's revenue change in Q3 2026?
VITAS +$14.1M (+3%); Roto-Rooter +$3.6M (+2%).